GlycoPharma Holding ApS: Financial statements 2021
CVR: 39691558
Source: annual report 2021, Danish Business Authority
01/07/2020 – 30/06/2021
GlycoPharma Holding ApS (CVR 39691558) has filed annual accounts for 2021. In 2021, the company reported a gross profit of DKK -12,118 and a net result of DKK -8,120 compared with DKK -618 the year before. Equity in the 2021 report amounted to DKK 413,935. The solvency ratio was 39.6%.
- Gross Profit
- DKK -12,118
- Profit/Loss
- DKK -8,120
- Equity
- DKK 413,935
- Total Assets
- DKK 1,044,253
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2021 | - | -12K | -8K | 414K | - |
| 2020 | - | -7K | -618 | 314K | - |
| 2019 | - | -8K | -6K | 315K | - |
Official annual report
Find more companies like GlycoPharma Holding ApS
Build lead lists with filters on industry, geography, size and financials, and export straight to Excel.
Try the lead list generatorAbout GlycoPharma Holding ApS
GlycoPharma Holding ApS is a Danish company of the type Anpartsselskab based in Odense SØ, founded in 2018. The company is registered under the industry Ikke-finansielle holdingselskaber. The management consists of Anders Boysen. The company's owners include SCIENCE VENTURES DENMARK A/S, Boysen Bio ApS and Zahle Holding ApS. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -12,525 and a net result of DKK -12,441 compared with DKK -15,360 the year before. Equity in the 2025 report amounted to DKK 684,140.